Lonza acquires Arch and looks to expand personal care business
Posted By Stephanie Tripp on July 10, 2011
“The acquisition of Arch Chemicals is the next logical step in Lonza’s life science focused strategy,” said Stefan Borgas, Lonza CEO.
“It will allow us to expand our non-pharma life science business to achieve a well-balanced profile based upon two world leading growth businesses – pharmaceutical contract manufacturing and microbial control.”
Borgas explained the acquisition of Arch Chemicals will further strengthen Lonza’s position in the microbial control market, insisting there will be substantial value for customers.
Global microbial control market
The global microbial control market is currently valued at approximately €7.2bn/ $10bn, and is growing at 4-6 per cent per annum.
The key end-use segments of the market are water treatment, hygiene, materials protection and personal care, and are growing at faster rates, with the largest markets being in North America, Europe and Japan. The fastest growing microbial control markets are Brazil, India, China and South Africa.
Upon completion of the transaction, Lonza will have the world’s leading microbial control business with 2010 pro-forma sales in this life science market of approximately €1.2bn/ $1.6bn, combining the complementary product solutions of both companies.
Similar Posts:
- Management changes in US and APAC for Lipo
- Inter Parfums enter in to ten-year license agreement with Anna Sui brand
- P&G open new planning centre in Ohio
- Research suggests green chemistry to take off over the next decade
- It’s here… SkinCare Ingredients 2011 opens its doors!
Comments
Leave a Reply